Organogenesis Holdings Inc. (ORGO) Insider Trading Activity

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

Show less

Over the last 12 months, insiders at Organogenesis Holdings Inc. have bought $40,093 and sold $2.62M worth of Organogenesis Holdings Inc. stock.

On average, over the past 5 years, insiders at Organogenesis Holdings Inc. have bought $636,111 and sold $1.81M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Driscoll Michael Joseph (director) — $26,688. Leibowitz Arthur S (director) — $13,405.

The last purchase of 5,000 shares for transaction amount of $13,405 was made by Leibowitz Arthur S (director) on 2026‑03‑09.